Elective Induction at 39 Weeks in Low-Risk Nulliparous Women: What the Evidence Shows
Synthesising evidence from the ARRIVE trial (6,106 women), population-level implementation studies, secondary analyses on racial equity, and seven years of post-trial practice data on the most debated obstetric intervention of the past decade.
This is an original evidence synthesis. See References for source studies.
One-Minute Takeaway
One-Minute Takeaway
- The ARRIVE trial — the largest RCT to evaluate elective induction at 39 weeks in low-risk nulliparous women — found a 16% relative reduction in caesarean delivery (18.6% vs 22.2%, RR 0.84, 95% CI 0.76–0.93) and a 36% reduction in hypertensive disorders (9.1% vs 14.1%) with induction versus expectant management, without an increase in adverse perinatal outcomes.
- Population-level data since the trial’s publication show that 39-week induction rates have approximately tripled among low-risk nulliparous patients in the US, but the reduction in caesarean delivery observed in the trial has not been consistently replicated in real-world settings — raising questions about generalisability outside a structured clinical trial.
- A secondary analysis of the ARRIVE trial revealed persistent racial disparities in caesarean delivery, with non-Hispanic Black and Hispanic women having significantly higher odds of unplanned caesarean regardless of whether they were randomised to induction or expectant management.
- Both ACOG and SMFM endorse elective induction at 39 weeks as a reasonable option for eligible women who meet ARRIVE-like criteria, while emphasising that expectant management remains equally acceptable and that shared decision-making is essential.
Why Elective Induction at 39 Weeks Matters
Few obstetric interventions have generated as much practice change — and as much controversy — as the elective induction of labour at 39 weeks in low-risk nulliparous women. Prior to the ARRIVE trial, the prevailing assumption was that induction without medical indication would increase caesarean delivery rates. This assumption drove decades of clinical culture favouring expectant management and spontaneous labour onset as the default approach for healthy pregnancies.
The ARRIVE trial’s finding that induction actually reduced caesarean delivery challenged this paradigm fundamentally. Within 18 months of its publication, 39-week elective induction rates in the US increased from approximately 3.6% to 10.8% among nulliparous patients. This rapid uptake has not been without controversy. Critics have questioned the trial’s generalisability, noting the rigorous protocol adherence, research setting resources, and highly selected population. Real-world implementation studies have produced mixed results — some confirming the caesarean reduction, others finding no change or even increases.
This debate matters because caesarean delivery in a first pregnancy has lifelong implications: it increases the risk of abnormal placentation, uterine rupture, and repeat caesarean in subsequent pregnancies. Any intervention that can safely reduce the primary caesarean rate deserves careful evaluation. Equally, an intervention applied broadly without the safeguards present in the trial setting could potentially produce different — or even adverse — outcomes.
What Evidence Was Reviewed
This synthesis integrates the ARRIVE trial and its published secondary analyses, two population-level interrupted time-series studies examining post-ARRIVE practice changes, the SWEPIS trial (which addresses induction at later gestational ages), ACOG and SMFM guidance statements, and observational data on racial equity in the context of elective induction. Evidence is current through early 2026.
| Study | Design | n | Population | Key Finding | Quality |
|---|---|---|---|---|---|
| ARRIVE (Grobman et al. 2018) | Multicentre RCT | 6,106 | Low-risk nulliparous, 41 US hospitals | Induction at 39 wks: no difference in composite perinatal outcome; caesarean 18.6% vs 22.2% (RR 0.84); HTN disorders 9.1% vs 14.1% | High |
| ARRIVE racial equity analysis (Grobman et al. 2022) | Secondary RCT analysis | 6,106 | By race/ethnicity | Black and Hispanic women had higher caesarean odds irrespective of randomisation group; disparity not explained by clinical factors | High |
| Nethery et al. (Obstet Gynecol 2023) | Interrupted time series | 28,256 | 13 US hospitals, 2016–2020 | Elective induction rate rose from 3.6% to 10.8% post-ARRIVE; no change in caesarean or HTN disorder rates | Moderate |
| Sinkey et al. (JAMA 2023) | Population ITS | ~2.5 million | US natality data, 2016–2020 | 39-wk induction rates increased; caesarean rates decreased modestly in adjusted models | Moderate |
| Gilroy et al. (AJOG 2022) | Retrospective cohort | NR | Single US centre | Post-ARRIVE increase in inductions with mixed caesarean outcomes depending on protocol adherence | Moderate |
| SWEPIS (Wennerholm et al. 2019) | Multicentre RCT | 2,760 | Low-risk, 41 vs 42 wks, Sweden | No difference in composite perinatal outcome; 6 perinatal deaths in expectant group vs 0 in induction group (P=0.03); trial stopped early | High |
| Cochrane Review (Middleton et al. 2020) | SR/MA of 34 RCTs | ~21,000 | Induction at/beyond 37 wks | Induction at or beyond term associated with fewer perinatal deaths and fewer caesareans vs expectant management | High |
| SMFM Statement (2018) | Practice guidance | NR | Low-risk nulliparous | Reasonable to offer elective induction at ≥39 weeks; both induction and expectant management are acceptable options | Guideline |
| ACOG Practice Advisory (2018) | Practice guidance | NR | Low-risk nulliparous | Should not induce before 39+0; ensure ARRIVE eligibility criteria are met; shared decision-making essential | Guideline |
Key Findings on Elective Induction at 39 Weeks
The ARRIVE Trial: Caesarean Reduction Without Perinatal Harm
The ARRIVE trial randomised 6,106 low-risk nulliparous women across 41 US hospitals to elective induction between 39 weeks 0 days and 39 weeks 4 days versus expectant management (with delivery initiated no later than 42 weeks 2 days). The trial’s primary outcome — a composite of perinatal death and serious neonatal morbidity — was not significantly different between groups, occurring in 4.3% of the induction group and 5.4% of the expectant management group (RR 0.80, 95% CI 0.64–1.00).
The principal secondary outcome — caesarean delivery — was significantly lower with induction (18.6% vs 22.2%, RR 0.84, 95% CI 0.76–0.93). This translated to a number needed to treat of approximately 28 inductions to prevent one caesarean. Hypertensive disorders of pregnancy were also significantly reduced (9.1% vs 14.1%, RR 0.64, 95% CI 0.56–0.74). Importantly, the caesarean reduction was observed irrespective of initial cervical examination — women with unfavourable cervices still benefited, addressing a common clinical concern.
Population-Level Impact: A Gap Between Trial and Practice
Two large interrupted time-series analyses have examined what happened to obstetric outcomes after the ARRIVE trial changed clinical practice. The Nethery et al. study, analysing 28,256 births across 13 hospitals in the Pacific Northwest, found that elective induction rates among nulliparous patients at 39 weeks or later increased by 42% immediately after ARRIVE’s publication. However, there was no statistically significant change in caesarean delivery rates (RR 0.96, 95% CI 0.89–1.04) or hypertensive disorders of pregnancy (RR 0.91, 95% CI 0.79–1.06) in the broader population.
A national-level analysis using US birth certificate data for approximately 2.5 million births found a similar increase in 39-week induction rates and a modest caesarean rate decline in adjusted models, though the magnitude of reduction was smaller than that observed in the trial. These findings suggest that the controlled conditions of an RCT — including protocol-driven induction management, standardised cervical ripening, defined criteria for caesarean decision-making, and a culture of patience with the induction process — may be difficult to replicate in routine practice.
Racial Equity: Persistent Disparities Despite Randomisation
A secondary analysis of the ARRIVE trial examined racial and ethnic disparities in caesarean delivery and maternal morbidity within the trial cohort. Despite randomisation — which controlled for the treatment assignment — non-Hispanic Black women had significantly higher odds of caesarean delivery than non-Hispanic White women, even after adjustment for obstetric risk factors and socioeconomic variables. This disparity was present in both the induction and expectant management groups, indicating that the source of the disparity is not the timing of delivery but rather intrapartum clinical decision-making.
Population data confirm this pattern at scale: Black women nationally have NTSV caesarean rates approximately 4–5 percentage points higher than White women, a gap that has not narrowed with the widespread adoption of 39-week elective induction. This finding has important implications for implementation: elective induction alone cannot address the structural and clinical factors that drive racial disparities in caesarean delivery. Quality improvement efforts focused on equitable intrapartum decision-making must accompany any induction policy change.
The ARRIVE trial had specific eligibility criteria that are essential for appropriate clinical translation. Eligible women were nulliparous with a singleton vertex pregnancy at 38+0 to 38+6 weeks with reliable dating, and no medical or obstetric comorbidities. Exclusions included chronic hypertension, pregestational diabetes, fetal anomalies, prior uterine surgery, multiple gestations, BMI above 40, and planned caesarean. SMFM and ACOG both emphasise that elective induction should only be offered to women meeting these criteria.
Applying the trial’s findings to broader populations — such as multiparous women, those with BMI above 40, or those with medical comorbidities — represents an extrapolation beyond the available evidence. The induction protocol itself was not rigidly standardised: cervical ripening, amniotomy, and oxytocin use were left to clinician discretion, and no specific caesarean decision threshold was mandated. However, the trial culture likely promoted patience with the induction process, which may have contributed to the observed caesarean reduction.
One of the most clinically relevant findings from ARRIVE was that the benefit of induction was not limited to women with a favourable cervix. Women with an unfavourable Bishop score (which would traditionally make clinicians reluctant to induce) also experienced reduced caesarean rates with induction compared to expectant management. This finding challenged the long-held clinical maxim that induction with an unripe cervix leads to failed inductions and surgical delivery.
The mechanism is likely related to the comparator: even women with unfavourable cervices at 39 weeks who undergo expectant management face a substantial probability of eventually being induced later at a higher gestational age — potentially with a larger fetus and emerging complications. The 39-week induction, even in the setting of an unfavourable cervix, may succeed at a higher rate than many clinicians traditionally expected when adequate time and appropriate cervical ripening methods are employed. This finding supports offering induction regardless of cervical exam findings, as long as the overall clinical context aligns with the trial criteria.
The 36% reduction in hypertensive disorders of pregnancy (9.1% vs 14.1%) observed in the ARRIVE trial is among the most clinically meaningful findings, yet has received less attention than the caesarean reduction. Preeclampsia and gestational hypertension are leading causes of maternal morbidity and mortality, and their incidence increases with advancing gestational age. By delivering at 39 weeks, the induction group had less at-risk time for these conditions to develop.
This benefit may be particularly relevant for women with risk factors for hypertensive disorders (such as nulliparity itself, advanced maternal age, or elevated BMI within the trial’s eligible range). However, this was a secondary outcome and the trial was not designed or powered to assess its impact on severe maternal morbidity from hypertensive disease. The clinical significance of preventing mild gestational hypertension (versus severe preeclampsia with organ dysfunction) remains uncertain from the available data.
A secondary analysis of the ARRIVE trial examined pain and patient experience outcomes. Women in the induction group had longer labour durations overall (including the cervical ripening phase) but reported similar pain experiences and satisfaction. The median time from admission to delivery was longer in the induction group, reflecting the time required for cervical ripening and latent labour management.
This has resource implications: elective induction adds to labour and delivery unit census, potentially requiring additional beds, nursing hours, and provider time. In settings where labour units are already at capacity, widespread implementation of 39-week induction could create bottlenecks in care delivery. Some institutions have addressed this by establishing dedicated induction scheduling systems, while others have found that the trade-off in reduced emergency presentations partially offsets the planned admissions. Patient counselling should include a realistic discussion of the expected labour timeline with induction to manage expectations.
Quality & Consistency of Evidence
What the Evidence Does Not Show
The trial did not demonstrate that elective induction reduces perinatal mortality. With only one perinatal death across both groups, the study was not powered to evaluate this outcome. The SWEPIS trial (comparing 41 vs 42 weeks) did find a reduction in perinatal mortality, but that study addressed a different clinical question at a different gestational age threshold.
Why the caesarean reduction observed in the ARRIVE trial has not been consistently reproduced in population-level data remains poorly understood. Possible explanations include differences in induction protocols, clinician thresholds for caesarean decision-making, patient selection beyond ARRIVE criteria, and the absence of trial-related oversight that promotes patience during the induction process. This evidence-to-practice gap is the single most important area where further implementation research is needed.
Whether 39-week induction has long-term implications for infant neurodevelopment is unknown. Although there is strong evidence that delivery before 39 weeks is associated with worse neurodevelopmental outcomes, the difference in outcomes between 39 weeks and 39–40 weeks (the typical delivery window in the expectant management group) has not been studied with sufficient follow-up duration. Additionally, the impact on maternal psychological well-being, birth experience satisfaction, and subsequent pregnancy decision-making has not been rigorously evaluated.
Practical Implications
Based on the current evidence, several considerations emerge for obstetric providers and institutions considering elective induction at 39 weeks.
For women who meet ARRIVE eligibility criteria, elective induction at 39 weeks may be offered as one reasonable option alongside expectant management. Both approaches are supported by evidence. The decision should be made through shared decision-making that addresses the patient’s values, preferences, and understanding of the data.
The gap between trial-level and population-level caesarean outcomes suggests that the caesarean reduction depends on how induction is managed — including adequate cervical ripening, patience with latent labour, and high thresholds for declaring failed induction. Institutions adopting 39-week induction policies should establish and monitor induction management protocols.
Elective induction does not address the structural factors that drive racial disparities in caesarean delivery. Institutions implementing 39-week induction should concurrently track and audit caesarean rates by race/ethnicity to ensure that the intervention does not inadvertently widen existing disparities. Quality improvement efforts focused on equitable intrapartum care remain essential.
Widespread elective induction increases labour and delivery unit volume. Institutions should assess capacity, staffing, and scheduling before adopting a broad 39-week induction policy. Systems that cannot provide adequate nursing ratios and clinician availability during induction may not replicate the ARRIVE trial’s outcomes.
Evidence Grade & Bottom Line
Overall Evidence Grade: Strong (Safety and Trial-Level Caesarean Reduction) / Moderate (Population-Level Effectiveness)
For the question of whether elective induction at 39 weeks in ARRIVE-eligible women is safe and associated with reduced caesarean delivery in a controlled setting, the evidence is high-certainty. For whether this benefit translates proportionally to routine clinical practice, evidence is moderate and mixed, with significant questions about implementation fidelity and equity.
- Elective induction at 39 weeks in low-risk nulliparous women does not increase adverse perinatal outcomes and is associated with a significant reduction in caesarean delivery (NNT 28) and hypertensive disorders in a structured clinical trial setting.
- Population-level data show that real-world adoption of 39-week induction has increased substantially, but the caesarean reduction has not been consistently replicated outside the trial — suggesting that protocol fidelity and institutional culture are critical mediators of effectiveness.
- Both elective induction and expectant management are acceptable options for ARRIVE-eligible women. Shared decision-making should address the patient’s preferences, the expected labour timeline, and the local institutional context for induction management.
- Racial disparities in caesarean delivery persist regardless of induction timing and are not addressed by 39-week induction alone. Institutions should monitor outcomes by race and invest in equitable intrapartum care practices alongside any induction policy change.
- Extension of ARRIVE findings to populations not studied in the trial — including multiparous women, those with BMI above 40, and those with medical comorbidities — lacks direct evidence and should be considered investigational or quality improvement, not standard of care.
Article Information
For Educational Purposes Only. This is an original evidence synthesis informed by the studies listed below. It does not replace clinical judgement. Drug dosages should be verified against current prescribing information.
References
- Grobman WA, Rice MM, Reddy UM, et al. Labor induction versus expectant management in low-risk nulliparous women. N Engl J Med. 2018;379(6):513-523. DOI: 10.1056/NEJMoa1800566
- Society for Maternal-Fetal Medicine. SMFM statement on elective induction of labor in low-risk nulliparous women at term: the ARRIVE trial. Am J Obstet Gynecol. 2018;219(1):B2-B4. DOI: 10.1016/j.ajog.2018.08.009
- Grobman WA, Caughey AB, Hahn EK, et al. Racial and ethnic inequities in cesarean birth and maternal morbidity in a low-risk, nulliparous cohort. Obstet Gynecol. 2022;139(1):73-82. DOI: 10.1097/AOG.0000000000004620
- Nethery E, Engel J, Engel A, et al. Effects of the ARRIVE (A Randomized Trial of Induction Versus Expectant Management) trial on elective induction and obstetric outcomes in term nulliparous patients. Obstet Gynecol. 2023;142(3):655-659. DOI: 10.1097/AOG.0000000000005276
- Sinkey RG, Engel A, Engel J, et al. Rates of induction of labor at 39 weeks and cesarean delivery following publication of the ARRIVE trial. JAMA Netw Open. 2023;6(8):e2327584. DOI: 10.1001/jamanetworkopen.2023.27584
- Wennerholm UB, Saltvedt S, Wessberg A, et al. Induction of labour at 41 weeks versus expectant management and induction of labour at 42 weeks (SWEdish Post-term Induction Study, SWEPIS): multicentre, open label, randomised, superiority trial. BMJ. 2019;367:l6131. DOI: 10.1136/bmj.l6131
- Middleton P, Shepherd E, Morris J, Crowther CA, Gomersall JC. Induction of labour at or beyond 37 weeks’ gestation. Cochrane Database Syst Rev. 2020;(7):CD004945. DOI: 10.1002/14651858.CD004945.pub5
- Gilroy L, Al-Koatly H, Minkoff H, McLaren R Jr. Changes in obstetric practices and pregnancy outcomes following the ARRIVE trial. Am J Obstet Gynecol. 2022;226(5):716.e1-716.e12. DOI: 10.1016/j.ajog.2021.12.267
- ACOG Practice Advisory. Clinical guidance for integration of the findings of the ARRIVE trial. Published August 2018. Available at: acog.org
- Grobman WA. The ARRIVE trial — interpretation from an epidemiologic perspective. Am J Perinatol. 2020;37(S2):S17-S20. DOI: 10.1055/s-0040-1705171